

Press release

Zurich, July 1, 2020

Xlife Sciences AG: Xlife Sciences waives early redemption of the privately placed convertible bond until July 1, 2023

This is intended to ensure that the largest amount of shares possible remain tradable and in free float.

About Xlife Sciences AG

Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.

For more information, please visit: www.xlifesciences.ch